Evidence map›Paper›PMID 18052604›Full record

ArticlePLoS medicine2007

Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation.

Jörg Schüpbach, Martin D Gebhardt, Zuzana Tomasik, Christoph Niederhauser, Sabine Yerly, Philippe Bürgisser, Lukas Matter, Meri Gorgievski, Rolf Dubs, Detlev Schultze and 7 more

Open access · goldAbstract readComparative StudyEvaluation Study
In one paragraph

Article in PLoS medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 87 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Jörg SchüpbachUniversity of Zurich, Swiss National Center for Retroviruses, Zurich, Switzerland. jorg.schupbach@access.uzh.ch
Martin D Gebhardt
Zuzana Tomasik
Christoph Niederhauser
Sabine Yerly
Philippe Bürgisser
Lukas Matter
Meri Gorgievski
Rolf Dubs
Detlev Schultze
Ingrid Steffen
Corinne Andreutti
Gladys Martinetti
Bruno Güntert
Roger Staub
Synove Daneel
Pietro Vernazza
Federal Office of Public Health · CHKantonsspital St. Gallen · CHUniversity of Zurich · CHClinique de La Source · CHScuola Cantonale di Commercio Bellinzona · CHSwiss Red Cross · CHUniversity Hospital of Lausanne · CHUniversity Hospital of Zurich · CHUniversity of Basel · CHUniversity of Bern · CHUniversity of St. Gallen · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKnowledge of the number of recent HIV infections is important for epidemiologic surveillance. Over the past decade approaches have been developed to estimate this number by testing HIV-seropositive specimens with assays that discriminate the lower concentration and avidity of HIV antibodies in early infection. We have investigated whether this "recency" information can also be gained from an HIV confirmatory assay. METHODS AND

findingsThe ability of a line immunoassay (INNO-LIA HIV I/II Score, Innogenetics) to distinguish recent from older HIV-1 infection was evaluated in comparison with the Calypte HIV-1 BED Incidence enzyme immunoassay (BED-EIA). Both tests were conducted prospectively in all HIV infections newly diagnosed in Switzerland from July 2005 to June 2006. Clinical and laboratory information indicative of recent or older infection was obtained from physicians at the time of HIV diagnosis and used as the reference standard. BED-EIA and various recency algorithms utilizing the antibody reaction to INNO-LIA's five HIV-1 antigen bands were evaluated by logistic regression analysis. A total of 765 HIV-1 infections, 748 (97.8%) with complete test results, were newly diagnosed during the study. A negative or indeterminate HIV antibody assay at diagnosis, symptoms of primary HIV infection, or a negative HIV test during the past 12 mo classified 195 infections (26.1%) as recent (< or = 12 mo). Symptoms of CDC stages B or C classified 161 infections as older (21.5%), and 392 patients with no symptoms remained unclassified. BED-EIA ruled 65% of the 195 recent infections as recent and 80% of the 161 older infections as older. Two INNO-LIA algorithms showed 50% and 40% sensitivity combined with 95% and 99% specificity, respectively. Estimation of recent infection in the entire study population, based on actual results of the three tests and adjusted for a test's sensitivity and specificity, yielded 37% for BED-EIA compared to 35% and 33% for the two INNO-LIA algorithms. Window-based estimation with BED-EIA yielded 41% (95% confidence interval 36%-46%).

conclusionsRecency information can be extracted from INNO-LIA-based confirmatory testing at no additional costs. This method should improve epidemiologic surveillance in countries that routinely use INNO-LIA for HIV confirmation.

Indexed as

Immunoenzyme TechniquesAIDS SerodiagnosisAlgorithmsAntibody AffinityAntigen-Antibody ReactionsBlotting, WesternDisease ProgressionFemaleHIV-1HIV-2HIV AntibodiesHIV InfectionsHIV SeropositivityHIV SeroprevalenceHumansMaleHIV Antibodies

Identifiers

PMID18052604
PMCPMC2100138
OpenAlexW2106159990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.